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The World Health Organization estimates that 15.4% of all cancers are attributable to infections and 9.9% are linked to viruses1,2. Cancers that are attributable to infections have 
a greater incidence than any individual type of cancer worldwide. 
Eleven pathogens have been classified as carcinogenic agents 
in humans by the International Agency for Research on Cancer 
(IARC)3. After Helicobacter pylori (associated with 770,000 cases 
worldwide), the four most prominent infection-related causes of 
cancer are estimated to be viral2: HPV4 (associated with 640,000 
cases), HBV5 (420,000 cases), hepatitis C virus (HCV)6 (170,000 
cases) and EBV7 (120,000 cases). It has been shown that viruses can 
contribute to the biology of multistep oncogenesis and are impli-
cated in many of the hallmarks of cancer8. Notably, the discovery of 
links between infection and cancer types has provided actionable 
opportunities, such as the use of HPV vaccines as a preventive mea-
sure, to reduce the global impact of cancer. The following character-
istics have been proposed to define human viruses that cause cancer 
through direct or indirect carcinogenesis9: (1) presence and persis-
tence of viral DNA in tumor biopsies; (2) growth-promoting activity 
of viral genes in model systems; (3) dependence of a malignant phe-
notype on continuous viral oncogene expression or modification of 
host genes; and (4) epidemiological evidence that a virus infection 
represents a major risk for the development of cancer.
The worldwide efforts of comprehensive genome and whole-tran-
scriptome analyses of tissue samples from patients with cancer have 
generated appropriate facilities for capturing information not only 
from human cells but also from other—potentially pathogenic—
organisms or viruses that are present in the tissue. A comprehensive 
collection of whole-genome and whole-transcriptome data from 
cancer tissues has been generated within the International Cancer 
Genome Consortium (ICGC) project PCAWG10, providing a unique 
opportunity for a systematic search for tumor-associated viruses.
The PCAWG Consortium aggregated whole-genome sequenc-
ing (WGS) data from 2,658 cancers across 38 tumor types that 
have been generated by the ICGC and The Cancer Genome Atlas 
(TCGA) projects. These sequencing data were reanalyzed with stan-
dardized, high-accuracy pipelines to align to the human genome 
(build hs37d5) and identify germline variants and somatically 
acquired mutations10. The PCAWG working group ‘Pathogens’ 
analyzed the WGS and whole-transcriptome sequencing 
(RNA-sequencing (RNA-seq)) data of the PCAWG consensus 
cohort (2,656 donors). Focusing on viral pathogens, we applied 
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Here, as part of the Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium, for which whole-genome and—for a sub-
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investigated potential viral pathogens using a consensus approach that integrated three independent pipelines. Viruses were 
detected in 382 genome and 68 transcriptome datasets. We found a high prevalence of known tumor-associated viruses such 
as Epstein–Barr virus (EBV), hepatitis B virus (HBV) and human papilloma virus (HPV; for example, HPV16 or HPV18). The 
study revealed significant exclusivity of HPV and driver mutations in head-and-neck cancer and the association of HPV with 
APOBEC mutational signatures, which suggests that impaired antiviral defense is a driving force in cervical, bladder and head-
and-neck carcinoma. For HBV, HPV16, HPV18 and adeno-associated virus-2 (AAV2), viral integration was associated with local 
variations in genomic copy numbers. Integrations at the TERT promoter were associated with high telomerase expression evi-
dently activating this tumor-driving process. High levels of endogenous retrovirus (ERV1) expression were linked to a worse 
survival outcome in patients with kidney cancer.
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three independently developed pathogen-detection pipelines 
‘Computational Pathogen Sequence Identification’ (CaPSID)11, 
‘Pathogen Discovery Pipeline’ (P-DiP) and ‘Searching for Pathogens’ 
(SEPATH) to generate a large compendium of viral associations 
across 38 cancer types. We extensively characterized the known and 
novel viral associations by integrating driver mutations, mutational 
signatures, gene expression profiles and patient survival data of the 
same set of tumors analyzed by the PCAWG Consortium.
Results
Identification of tumor-associated viruses. To identify the pres-
ence of viral sequences, we explored the WGS data of 5,354 tumor–
normal samples across 38 cancer types, and 1,057 tumor RNA-seq 
data across 25 cancer types (Supplementary Tables 1, 2, 20). In 
total, 195.8 billion reads were considered for analysis, as they were 
not sufficiently aligned to the human reference genome in the 
PCAWG-generated alignment. The remaining reads ranged from 
28,036 to 800 million reads per WGS and up to 120 million reads 
per RNA-seq tumor sample (Fig. 1a, Extended Data Fig. 1a–c). 
Viral sequences were detected and quantified independently by the 
three recently developed pathogen-discovery pipelines CaPSID, 
P-DiP and SEPATH. The estimated relative abundance of a virus 
was calculated as viral reads per million extracted reads (PMER) at 
the genus level to improve consistency between pipelines. To mini-
mize the rate of false-positive hits in virus detection, we applied a 
strict threshold of PMER > 1 supported by at least three viral reads 
as suggested in previous studies11,12. Virus detection in a sample 
by at least two pipelines was considered to be a consensus hit. In 
total, 532 genera were considered for the extensive virus search in 
at least two of the pipelines (Extended Data Fig. 1d, Supplementary 
Table 18). Filtering of suspected viral laboratory contaminants was 
achieved through P-DiP, by examining each assembled contig of 
viral sequence segments for artificial, non-viral vector sequences 
and inspecting virus genome coverage across all positive samples 
(Extended Data Fig. 2a). The most frequent hits prone to suspected 
contamination were lambdavirus, alphabaculovirus, microvirus, 
simplexvirus, hepacivirus, cytomegalovirus (CMV), orthopoxvirus 
and punalikevirus; these were observed across many tumor types 
(Fig. 1b). For example, mastadenovirus showed an uneven genome 
coverage that could result from contaminating vector sequences. 
Therefore, we analyzed the virus detections across sequencing dates 
(Extended Data Fig. 2b) to assess any batch effect indicative of a 
contaminant; in mastadenovirus, we identified an association with 
sequencing date in early-onset prostate cancer regardless of tumor–
normal state. We conclude that our mastadenovirus detections are 
due to a contamination that occurred across projects worldwide for 
which similar patterns could be identified.
We generally observed a strong overlap of the genera identi-
fied across pipelines (Extended Data Fig. 1e, Supplementary Tables 
6, 7, 11). From the WGS dataset, we identified 321, 598 and 206 
virus–tumor pairs using P-DiP, CaPSID and SEPATH, respectively 
(Fig. 2a; overlap after random permutation of detections, Extended 
Data Fig. 3a, Supplementary Tables 3–5). The number of hits 
derived from the RNA-seq dataset differed between the pipelines 
(virus–tumor pairs: 101 for P-DiP, 83 for CaPSID, 41 for SEPATH; 
Fig. 2b, Supplementary Tables 8–10). SEPATH, which used a k-mer 
approach, detected the lowest number of virus hits and was the least 
sensitive. Despite this, the identified viruses matched well with the 
consensus (DNA 90%, RNA 95%). P-DiP, which was based on an 
assembly and BLAST approach, detected more hits with 59% of 
the DNA and 54% of the RNA hits in the consensus set, whereas 
CaPSID, which was the most sensitive, implemented a two-step 
alignment process complemented with an assembly step and iden-
tified 60% (DNA) and 80% (RNA) hits within the consensus set. 
Although the majority of the virus hits from RNA-seq (n = 61 out 
of 68 consensus hits based on RNA-seq) overlapped with the WGS 
data, a lower fraction of detections from the WGS data were present 
in the RNA-seq data (n = 61 out of 168 of 382 consensus hits based 
on WGS with available RNA-seq data), emphasizing the importance 
of DNA sequencing for generating an unbiased catalog of tumor-
associated viruses. This difference can also be attributed to the viral 
life cycle, as viral gene expression can be minimal during incuba-
tion or latent phases13. Contrasting virus-positive and virus-nega-
tive samples within each organ type shows that the organ system, 
as expected, has a significant influence, but virus positivity does not 
(P < 2 × 10−16, analysis of variance modeling of candidate reads that 
are dependent on organ system and virus positivity; Extended Data 
Fig. 1c). This indicates that virus-positive tumors were not detected 
owing to a higher number of candidate reads; this is consistent 
with the fact that the viral reads in most cases do not substantially 
contribute to the reads analyzed. In total, 86% of the sequence hits 
detected in WGS and RNA-seq data were found to be from dou-
ble-stranded DNA viruses and double-stranded DNA viruses with 
reverse transcriptase (Fig. 1c, Supplementary Table 19). This could 
be attributed to (1) a higher frequency of tumor-associated viruses 
from these genome types3, (2) a larger sequencing dataset for WGS 
compared with RNA-seq, (3) a potential limitation of our analysis 
due to DNA and RNA extraction protocols that are less likely to 
include single-stranded DNA or RNA viruses or (4) the selection 
bias of tumor entities included in the PCAWG study (Fig. 1c).
The virome landscape across 38 distinct tumor types. We used 
a consensus approach that resulted in a reliable set of 389 dis-
tinct virus–tumor pairs from WGS and RNA-seq data (Fig. 2a–d). 
Overall, 23 virus genera were detected across 356 patients with can-
cer (13%). The top-five most-prevalent viruses (lymphocryptovirus, 
orthohepadnavirus, roseolovirus, alphapapillomavirus and CMV) 
account for 85% of the consensus virus hits in tumors (n = 329 out 
of 389). Among these five prevalent virus genera, three have been 
well described in the literature as drivers of tumor initiation and 
progression9: (1) lymphocryptovirus (n = 145 samples (5.5%); for 
example, EBV) is the most common viral infection across a variety 
of tumor entities that mainly occur in the gastrointestinal tract and 
shows a much lower prevalence in the matched non-malignant con-
trol samples (n = 82 (3%); Fig. 2c); (2) orthohepadnavirus (n = 67 
(2.5%); for example, HBV) is—as expected—the most frequent 
among liver cancer with HBV present in 62 of 330 donors (18.9%); 
and (3) alphapapillomavirus (discussed below). Lymphocryptovirus 
(n = 11), orthohepadnavirus (n = 18) and alphapapillomavirus 
(n = 32) were detected in both RNA-seq and DNA-sequencing data 
(Fig. 2c, left), of which alphapapillomavirus was the most frequent 
(32 out of 39 consensus hits). This is consistent with the constitu-
tive expression of viral oncogenes in cancers associated with these 
viruses, a parameter that supports a direct role in carcinogenesis9. 
An in-depth analysis of the virus genome equivalents per human 
tumor genome equivalent, which considers genome sizes, cover-
age and tumor purity, showed overall low viral genome equiva-
lents even for established tumor viruses (Extended Data Fig. 3c, 
Supplementary Table 12). Evidence of a mouse mammary tumor 
virus (MMTV, PMER = 3.4) was detected in one renal carcinoma 
sample and in none of the 214 analyzed breast cancer samples. 
Previous work has suggested that MMTV may have a role in breast 
cancer but our comprehensive search of viral sequences could not 
identify any MMTV-positive case in breast cancer that would sup-
port this claim.
Roseolovirus and alphatorquevirus show a higher number of hits 
in non-malignant control samples, which were mainly derived from 
blood cells (Fig. 2c). For example, we identified 59 patients as rose-
olovirus-positive (human herpesvirus (HHV)-6A, HHV-6B and 
HHV-7) in their tumors (pancreas, 6%; stomach, 8%; colon/rectum, 
8.3%) and 90 patients positive in the non-malignant control sam-
ples. Considering the known cell tropism of roseolovirus for B and 
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Fig. 1 | Overview, design and summary statistics. a, Workflow to identify and characterize viral sequences from the WGS and RNA sequencing of tumor 
and non-malignant samples. Viral hits were characterized in detail by using several clinical annotations and resources generated by PCAWG. The red line 
represents the median. CNS, central nervous system. b, Identified viral hits in contigs that showed higher viral reads PMER for artificial sequences such as 
vectors than for the virus. All viruses that occurred in at least 20 primary tumor samples in the same contig together with an artificial sequence are shown. 
c, Summary of the viral search space used in the analysis grouped by virus genome type. The number of virus-positive tumor samples is indicated in the 
outer rings (PMER log scale for WGS and RNA-seq data) as detected by any of the pipelines. Taxonomic relations between the viruses are indicated by the 
phylogenetic tree. dsDNA, double-stranded DNA; dsDNA-RT, double-stranded DNA with reverse transcriptase; dsRNA, double-stranded RNA; ssDNA, 
single-stranded DNA; ssRNA-RT: single-stranded RNA with reverse transcriptase; ssRNA, single-stranded RNA; dsRNA, double-stranded RNA.  
The fractions of hits in WGS and RNA-seq data are depicted as stacked bar graphs.
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T  cells15, we asked whether immune infiltration would be higher 
in roseolovirus-positive tumors. However, we could not identify 
a stronger contribution of immune cells in virus-positive tumor 
cases as estimated using CIBERSORT14 (false-discovery rate (FDR)-
corrected P > 0.05 for pancreas; Extended Data Fig. 4a). Therefore, 
consistently with current knowledge (reviewed in ref. 16), we can-
not confirm a link between roseolovirus and immune-cell content 
or tumor development. Furthermore, we could not identify actively 
transcribed viral genes for roseolovirus and alphatorquevirus at 
the transcriptome level. This is in agreement with the latent state 
of these viruses in blood mononuclear cells15, and their transmis-
sion through blood transfusions17. CMV was found, as expected18, 
after identification and removal of contaminations in both stomach 
tumors (n = 13) and the adjacent non-malignant tissue (n = 11). In 
line with a recent publication19, we could not detect CMV in the 
294 tumors of the central nervous system (146 medulloblastomas, 
89 pilocytic astrocytoma, 41 glioblastomas and 18 oligodendrogli-
omas) that were analyzed. Therefore, a previously debated role of 
this virus is not supported. Notably, we did not identify a significant 
enrichment of co-infection of multiple viruses in any tumor type 
(Extended Data Fig. 3d).
Incidence of HBV. HBV was most frequently detected in liver cancers 
(n = 62). Compared with the histopathological gold-standard HBV 
PCR test20,21 (n = 228), the WGS-based consensus detections had the 
same high specificity (96.1%) and a high sensitivity (84.0%), indi-
cating that HBV detection using WGS is reliable (Fig. 3a, Extended 
Data Fig. 4b, Supplementary Table 13). Furthermore, five out of 
the seven cases that were positive using WGS but negative for HBV 
PCR showed positivity for HBAg, indicating that the WGS analysis 
has a high sensitivity. In summary, the precision (85.7%) and recall 
(84%) for the detection of HBV based on around 30-fold-coverage 
WGS data were comparable to those of targeted PCR. We confirmed 
a significant exclusivity between HBV infection and mutations in 
CTNNB1, TP53 and ARID1A that was found in a larger liver can-
cer cohort analyzed by high-throughput sequencing (FDR-corrected 
P = 5.35 × 10−6, 0.0023 and 0.0023, respectively; DISCOVER22)23.
Detection of EBV. EBV was detected in many different tumor enti-
ties and normal samples (Fig. 2c). When comparing the PMER of 
EBV in tumor and matched normal samples, we see a stronger con-
tribution in matched normal samples from matched solid tissue or 
tissue adjacent to the tumor (Extended Data Fig. 4c). For samples 
that contained reads for EBV in WGS and with available RNA-seq 
data, the absolute score for immune cells based on CIBERSORT14 
was not significantly different between virus-positive and virus-
negative samples (FDR-corrected P > 0.05 for colon/rectum, head-
and-neck, lymphoid and stomach; Extended Data Fig. 4a). In 
summary, there is no evidence that the detection of EBV is due to 
infiltrating immune cells. This indicates the presence of EBV in the 
respective organs. On the basis of the expression data available for 
the tumor samples, we identified viral transcripts of the latent as well 
as lytic phase of the viral life cycle (Fig. 3b, Extended Data Fig. 4d, 
Supplementary Table 13). Eight of the nine tumors that expressed 
lytic EBV transcripts were from stomach cancers, confirming the 
active contribution of EBV to gastric cancer24.
Identification of alphapapillomaviruses. Alphapapillomaviruses 
were mainly detected in head-and-neck cancers (n = 18 out of 57), 
cervical cancers (n = 19 out of 20) and in two bladder cancer 
cases out of 23, in agreement with previous studies4,25,26. There 
is also supporting evidence for 32 out of 39 alphapapillomavi-
rus hits in the whole-transcriptome data (Fig. 2c). We observed 
only one HPV subtype per tumor according to the P-DiP results 
and HPV16 was the dominant type in cervical (n = 11) and head-
and-neck (n = 15) tumors, followed by HPV18, which was present 
in only cervical cancer (n = 6). As reported previously27, HPV33 
was identified in head-and-neck (n = 3) and cervical (n = 1) 
tumors. Different HPV variants, type 6 and 45, were detected in 
bladder cancer.
In head-and-neck cancer, HPV-positive tumors exhibited an 
almost complete mutual exclusivity with mutations in known drivers 
such as TP53, CDKN2A and TERT (FDR-corrected P = 1.73 × 10−5, 
1.73 × 10−5 and 0.012, respectively; multiple testing corrected for 
presented mutations in EBV and HPV, DISCOVER22) (Fig. 3c, 
Supplementary Table 13), as reported previously25, which could be 
explained by the mutation-independent inactivation of TP53 due 
to the human papillomaviruses28,29,30. Furthermore, we found that 
mutational signature 2 was enriched in alphapapillomavirus-positive 
cases of head-and-neck cancer31 (FDR-corrected P = 0.02; Fig. 3d, 
Supplementary Tables 12, 22). In addition, the expression of 
APOBEC3B is significantly higher in virus-positive head-and-neck 
cancers compared with virus-negative cancers32 (P = 1.6 × 10−4; Fig. 3f). 
However, we did not observe enrichment of APOBEC signatures 
and changes in expression in EBV-positive samples found in the 
cervix or in other tissues.
Distinct expression profiles between virus-positive and virus-
negative tumors in head-and-neck cancer were observed33 (Fig. 3e, 
Supplementary Table 23). Analyzing the immune cells estimated by 
CIBERSORT, we identified a significant increase in macrophages 
and T-cell signals in alphapapillomavirus-positive head-and-neck 
cancers (P = 0.004, 0.012 and 0.012 for follicular helper, CD8 
and regulatory T  cells, respectively, and P = 0.018 for M1 macro-
phages; FDR corrected for all viruses and cell types tested; Fig. 3g, 
Supplementary Table 24). Our integrative analysis of HPV recon-
firms many of the findings related to HPV infection, illustrating the 
potential of our systematic approach in identifying and character-
izing tumor-associated viruses.
Activation of endogenous retroviruses linked to outcome. 
Human endogenous retroviruses (HERV) are integrations in the 
human DNA that originate from infection of germline cells by ret-
roviruses over millions of years34 and contribute over 500,000 indi-
vidual sites, or 2.7% of the overall sequence the human genome35,36. 
ERVs were identified by all three pathogen-detection pipelines but 
were filtered by CaPSID and SEPATH. In addition, an alignment-
based approach was used to detect HERV sequences that were 
embedded in the human reference genome that could be missed by 
the pipelines by focusing only on non-human reads. In this study, 
we quantified the expression of HERV-like long terminal repeat ret-
rotransposons that were categorized into several clades by Repbase37 
as ERVL, ERVL-MaLR, ERV1, ERVK and ERV (Supplementary 
Table 14). In comparison to the other HERV families, ERV1 shows 
Fig. 2 | Consensus for detected viruses in WGS and RNA-seq data. Number of genus hits among tumor samples for the three independent pipelines and 
the consensus set defined by evidence from multiple pipelines. a, Analysis based on WGS. b, Analysis based on whole-transcriptome sequencing.  
c, Heat map showing the total number of viruses detected across various cancer entities. The sequencing data used for detection are indicated among the 
total number of hits (WGS, blue; RNA sequencing, green). The fraction of virus-positive samples is shown at the top and the type of non-malignant tissue 
used in the analysis is indicated if more than 15% of the analyzed samples are from a respective tissue type (solid tissue, lymph node, blood or adjacent 
to primary tumor). d, t-SNE clustering of the tumor samples based on PMER of their consensus virome profiles, using Pearson correlation as the distance 
metric. Major clusters are highlighted by indicating the strongest viral genus and the dominant tissue types that are positive in that cluster. Dot size 
represents the viral reads PMER.
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the strongest expression on average (Fig. 4a) and ERVK the highest 
fraction of active loci (Fig. 4b). By analyzing the expression of 
HERVs, we could identify strong expression of ERV1 in chronic 
lymphocytic leukemia compared with all other tumor tissues and 
adjacent normal tissues (Fig. 4c). However, we could not identify a link 
between transcriptionally active stemness markers (OCT3/4, SOX2 
and KLF4) and increased HERV expression, in contrast to a previous 
report38 (Spearman rank correlation <0.35; Extended Data Fig. 5). 
WGS RNA-seq Solid tissue Blood derived Lymph node Tissue adjacent to primary
Consensus
SePATH
CaPSID
P-DiP
Number of hits
382
190
361
185
131
237
389
21
59%
60%
90%
49.5%
Number of hitsWGS (tumor)a
c
d
b
68
58
67
39
43
16
61
2
57%
80%
95%
53%
RNA-seq (tumor)
Unique to one pipeline
Evidence from 
multiple pipelines
Consensus set
WGS and RNA-seq
0 200 400 600 800 0 50 100
Lymphocryptovirus
(EBV)
Orthohepadnavirus
(HBV)
Roseolovirus
(HHV-6B)
Alphapapillomavirus
(alphapapillomavirus 7 and 9)
Gammaretrovirus
(murine leukemia virus)
CMV
(HCMV)
Alphatorquevirus
(Torque teno virus 5)
Lentivirus
(HIV)
0 150
Total number of hits
75
Non-malignant
Tumor
0 15075
Lymphocryptovirus
Orthohepadnavirus
Roseolovirus
Alphapapillomavirus
Gammaretrovirus
CMV
Alphatorquevirus
Lentivirus
Bi
lia
ry
M
ye
lo
id
Bo
ne
/s
of
t
Bl
ad
de
r
Th
yr
oi
d
O
va
ry
Ut
er
us
Lu
ng
Sk
in
Pr
os
ta
te
Ki
dn
ey
Co
lo
n/
re
ct
um
Br
ea
st
CN
S
Ly
m
ph
oi
d
Ce
rv
ix
Es
op
ha
gu
s
H
ea
d/
ne
ck
St
om
ac
h
Pa
nc
re
as
Li
ve
r
0
100 Fraction of
tum
or sam
ples (%)
–30 –20 –10 0 10 20
–20
–10
0
10
20
30
40
t-
SN
E 
2
t -SNE 1
PMER:
1 10 20
Orthohepadnavirus
Liver
Alphapapillomavirus
Cervix, head/neck, bladder
Roseolovirus
Pancreas
CMV
Stomach
Gammaretrovirus
Pancreas
Lymphocryptovirus
Stomach, esophagus, colon
13
62
2
1
10
21
2
8
1
26
6
13
2
2
16
2
18
23
3
3
2
1
19
12
2
1
4
1
4
1
3
1
2
2
3
1
10
5
6
1
4
1
5
2
3
1
7
1
1
3
1
2
3
2
1
1
1
1
2
2
1
1
6
13
13
1
22
3
1
19
14
11
1
1
2
5
1
1
2
1
1
2
2
1
2
11
2
4
4
1
5
1
1
1
4
3
1
5
15
3
1
2
4
2
2
1
4
1
1
1
2
5
1
1
1
1
1
3
3
2
1
1
Non-malignant:
NATuRE GENETICS | www.nature.com/naturegenetics
Articles NATuRE GENETICs
New data suggest that expression of HERVs is associated 
with prognosis in clear cell renal cell carcinoma39. Analyzing HERV 
expression in relation to patient survival, we found that high 
ERV1 expression in kidney cancer was linked to worse survival 
outcome (P = 0.0081; log-rank test; Fig. 4d, Extended Data Fig. 6, 
Supplementary Table 15).
Genomic integration of viral sequences. Viral integration into the 
host genome has been shown to be a causal mechanism that can 
lead to the development of cancer40. This process is well-established 
for HPVs in cervical, head-and-neck and several other carcinomas, 
and for HBV in liver cancer41,42.
Low-confidence integration events were detected for HHV4 
(gastric cancer and malignant lymphoma) and HPV6b (head-
and-neck and bladder carcinoma), whereas integration events 
with high confidence were demonstrated for HBV (liver cancer), 
AAV2 (liver), HPV16 and HPV18 (in both cervical and head-and-
neck carcinoma). Most of these integration events were found to 
be distributed across chromosomes and a significant number of 
viral integrations occurred in the intronic (40%) regions whereas 
only 3.4% of integrations was detected in gene coding regions 
(n = 84 intronic versus n = 31 other regions excluding intergenic 
regions, two-sample test for equality of proportions, P = 7.0 × 10–12; 
Extended Data Fig. 7a–d).
HBV was found to be integrated in 36 liver cancer specimens 
out of 61 patients who were identified to be HBV positive. Notably, 
genomic clusters of viral integrations were identified in TERT 
(number of integration sites within a genomic cluster (NGC) of 6), 
KMT2B (NGC = 4)—which was recently identified to be a likely 
cancer driver gene43,44—and RGS12 (NGC = 3) (Extended Data Fig. 
7e). Furthermore, two or more integration events in individual 
samples were observed in the gene (or gene promoter) regions 
of CCNE1, CDK15, FSIP2, HEATR6, LINC01158 (also known as 
PANTR1), MARS2 and SLC1A7 (Fig. 5a). Additional events with 
two integration sites were also detected within a distance of 50 kb 
from CLMP, CNTNAP2 and LINC00359 genes. Integration events 
at TERT were found to recur in five different liver cancer samples. 
One sample had a genomic cluster of three viral integration events 
within TERT and four samples contained a single integration event 
in the TERT promoter, or 3′ or 5′ untranslated regions (UTR) 
(Supplementary Table 17). When comparing gene expression in 
samples with virus integration to those without, we found that 
only TERT was overexpressed (fold change ≥2.0) in two liver can-
cer samples (Fig. 5e). Additional genes with increased expression 
that were influenced by integration events include TEKT3, CCNA2, 
CDK15 and THRB (Fig. 5a).
There was a significant association between HBV viral integra-
tions and somatic copy-number alterations (SCNAs, Fig. 5c). For 
samples with HBV integration events, the number of SCNAs was 
higher on average in the vicinity of viral integration sites (within 
1 Mb) compared with samples without HBV integration (mean 4.2 
versus 2.3, P = 7.4 × 10−3; two-sided paired t-test). No evidence of an 
SCNA association was seen for other integrated viruses like HPV16 
and HPV18 (Extended Data Fig. 8a,b).
HPV18 integration events were detected in seven tumors in total 
(Fig. 5b), with the most notable clusters of integration events that 
affected TALDO1 (NGC = 4) in cervical cancer samples (Extended 
Data Fig. 7g).
In 20 samples, HPV16 integration events were detected. 
Genomic clusters of viral integration sites were identified in cer-
vical and head-and-neck cancer samples (Extended Data Fig. 7f). 
None of these multiple integration events were observed to recur 
across patients (Fig. 5b). Integration events were also observed in 
two different long noncoding RNAs (lncRNAs), LINC00111 and 
the plasmacytoma variant translocation 1 gene (PVT1), an onco-
genic lncRNA45,46. Expression of both genes is strongly increased 
in the cases with HPV16 integration (Extended Data Fig. 8f, 
Supplementary Table 17).
Using the PCAWG SNV calls10, we found a significant increase in 
the number of mutations that occurred within ±10,000 bp of high-
confidence viral integration sites (average number of mutations per 
sample, 0.41 (HPV16+) versus 0.14 (HPV16−), P = 0.02; one-sided 
paired t-test, alternative greater, Extended Data Fig. 8c,d). Notably, 
the integration sites are—compared with a random genome back-
ground—enriched in proximity (<1,000 bp) to common fragile sites 
(P = 0.0018, Kolmogorov–Smirnov test). These results suggest that 
HPV16 integration reflects either characteristics of chromatin fea-
tures that favor viral integration, such as fragile sites or regions with 
limited access to DNA repair complexes, or the influence of inte-
grated HPV16 on the host genome. Such a correlation was not seen 
for the integration sites of other viruses (Extended Data Fig. 8e). 
Finally, a single AAV2 integration event located in the intronic 
region of the cancer driver gene KMT2B47 was detected in one liver 
cancer sample.
Identification of novel viral species or strains. De novo analysis 
using the CaPSID pipeline has generated 56 different contigs that 
have been classified into taxonomic groups at the genus level by 
CSSSCL48. After filtering de  novo contigs for their homology to 
known reference sequences, we identified 29 contigs in 28 differ-
ent tumor samples that showed low sequence similarity (on average 
63%) to any nucleotide sequence contained in the BLAST database. 
In this respect, our analysis has shown that WGS and RNA-seq 
can be used to identify isolates from potentially new viral species. 
However, the total numbers of novel isolates were low in compari-
son to viral hits to well-defined genera (Fig. 2c). These de  novo 
Fig. 3 | Virus-specific findings. a, HBV detections, validations and driver mutations in liver cancer. The asterisk indicates mutual exclusivity between HBV 
detection and somatic driver gene mutations. Red boxes represent virus-positive tumor samples, purple boxes show viral genomic integrations, green 
boxes indicate driver mutations and gray boxes represent missing data. b, Virus detections in gastric cancer samples, indication of virus phase (lytic/
latent, dark red) and driver mutations (green). A yellow color indicates donors with virus-positive non-malignant samples. The gray box refers to samples 
with available RNA-seq data. c, Virus detections (red) and driver mutations (green) in cervix (blue) and head-and-neck cancer (brown). The asterisk 
indicates mutual exclusivity between alphapapillomavirus detections and somatic driver gene mutations. d, Alphapapillomavirus detection and exposures 
of mutational APOBEC signatures SBS2 and SBS13. Sample sizes are shown at the bottom. A two-sided Wilcoxon rank-sum test showed a significant 
difference (P = 0.02) of mutational signature exposure between virus-positive and virus-negative head-and-neck tumor samples. The black line indicates 
the median for each group. e, Gene expression analysis based a t-SNE map of head-and-neck cancer samples shows a distinct gene expression profile 
for virus-positive samples. Virus-positive and virus-negative samples are shown as red and gray dots, respectively. f, The violin plot of APOBEC3B gene 
expression for alphapapillomavirus-positive and alphapapillomavirus-negative samples in cervix and head-and-neck cancer (FDR-corrected two-sided 
Wilcoxon rank-sum test, P = 1.6 × 10−4). FPKM, fragments per kilobase of transcript per million mapped reads. The center line represents the median, and 
the upper and lower boundaries of the violin plot refer to the maximum and minimum values, respectively. g, Tumor-infiltrating immune cells as quantified 
by CIBERSORT using RNA-seq samples from patient with head-and-neck cancer. All four cell types showed significant enrichment of immune cells in 
virus-positive samples (FDR-corrected two-sided Wilcoxon rank-sum test, n = 24 virus negative versus 18 virus positive). Tukey box plots show the median 
(the middle line) and the 25–75th percentiles (the box); the whiskers show 1.5× the interquartile range from the lower and upper quartile.
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contigs were not enriched for a specific tumor entity but rather were 
distributed across cancer types including bladder, head-and-neck 
and cervical cancers (Extended Data Fig. 9).
Discussion
Searching large pan-cancer genome and whole-transcriptome datas-
ets enabled the identification of a high percentage of virus-associated 
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cases (16%). In particular, analysis of tumor genomes, which were 
sequenced on average to a depth of at least 30-fold coverage, iden-
tified considerably more virus-positive cases than investigations 
of whole-transcriptome data alone, which is the search space ana-
lyzed in most previous virome studies. This is probably mainly 
due to viruses with no or only weak transcriptional activity in the 
given tumor tissue. Co-infections, generally believed to indicate 
a weak immune system, were very rare (Extended Data Fig. 3d). 
This could, however, also be the result of selection processes 
during tumorigenesis.
Although universal criteria for a causality of viral pathogens 
are prone to errors, it is worthwhile to look at individual features 
that might support a potentially pathomechanistic contribution of 
a given pathogen. These include aspects that affect the expression 
of host factors (for example, after viral integration) or the mutual 
exclusivity of the presence of viral genomes and other host factors, 
Histology
Adenocarcinoma
Chronic lymphocytic leukemia
Diffuse glioma
Hepatocellular carcinoma
Liposarcoma, soft tissue
Lobular carcinoma
Mature B-cell lymphoma
Melanoma
RCC (distal tubules)
RCC (proximal tubules)
Sarcoma, soft tissue
Squamous cell carcinoma
Transitional cell carcinoma
–4 –2 0 2 4 6
log2[TPM]
0
100
200
0
20
40
Ad
en
oc
ar
cin
om
a 
(n 
=
 
34
1)
Ch
ro
ni
c 
lym
ph
oc
yt
ic 
le
uk
em
ia
 (n
 
=
 
31
)
D
iff
us
e 
gl
io
m
a 
(n 
=
 
46
)
H
ep
at
oc
el
lu
la
r c
ar
cin
om
a 
(n 
=
 
49
)
Li
po
sa
rc
om
a,
 s
of
t t
iss
ue
 (n
 
=
 
18
)
Lo
bu
la
r c
ar
cin
om
a 
(n 
=
 
6)
M
at
ur
e 
B-
ce
ll 
lym
ph
om
a 
(n 
=
10
1)
M
el
an
om
a 
(n 
=
 
33
)
R
CC
 (d
ist
al 
tub
ule
s) 
(n 
=
 
45
)
R
CC
 (p
rox
im
al 
tub
ule
s) 
(n 
=
 
69
)
Sa
rc
om
a,
 s
of
t t
iss
ue
 (n
 
=
 
15
)
Sq
ua
m
ou
s 
ce
ll c
ar
cin
om
a 
(n 
=
 
10
7)
Tr
an
si
tio
na
l c
el
l c
ar
ci
no
m
a 
(n 
=
 
23
)
Specimen
Non-malignant
(tissue adjacent to primary)
Tumor
Specimen
Histology
P = 0.0081
0
0.25
0.50
0.75
1.00
S
ur
vi
va
l p
ro
ba
bi
lit
y
+ +ERV1-high ERV1-low
ERV1 expression in kidney (TPM > 16.3)
71 19 8 1 0
42 30 20 7 1ERV1-low
ERV1-high
0 1,000 2,000 3,000 4,000
Time (d)
0
50
100
0 25 50 75 100
Samples (%)
F
ra
ct
io
n 
of
 a
ct
io
n 
of
ac
tiv
e 
si
te
s 
(T
P
M
 >
 0
.2
) 
(%
) HERV family
ERVL (n = 102)
ERVL−MaLR (n = 80)
ERV1 (n = 260)
ERVK (n = 37)
ERV (n = 3)
ERVL
ERV1
ERVK
ERV
ERVL-MaLR
E
xp
re
ss
io
n 
(T
P
M
)
E
xp
re
ss
io
n 
(T
P
M
) ERV1
ERVK
a
b
d
c
Fig. 4 | Expression of ERVs. a, Heat map showing the expression of HERV across all tumor samples. HERV transcripts per million (TPM) were 
grouped by family and summed up. Hierarchical clustering was performed by family according to Manhattan distance with complete linkage after log2 
transformation of HERV TPM expression values.(RCC, renal cell carcinoma). b, Fraction of active loci in the genome with a TPM > 0.2 plotted against the 
fraction of samples. c, TPM-based expression of the highly expressed HERVs ERV1 and ERVK across tumor types. n, number of analyzed tumor samples. 
Violin plots are shown; red dots indicate the median. The upper and lower boundaries of the violin plot extend to the maximum and minimum values. 
d, Survival difference between patients with kidney cancer expressing high (red) and low levels (blue) of ERV1. Kaplan–Meier curve shows the overall 
survival of patients (n = 113) with high and low levels of ERV1 with a cut-off of 16.3 TPM (log-rank test P = 0.0081). The number of patients at risk is 
shown at the bottom.
NATuRE GENETICS | www.nature.com/naturegenetics
ArticlesNATuRE GENETICs
which are already known to have a role in the etiology of a given 
tumor type. Such aspects need to be carefully considered when dis-
cussing what strengthens the potentially pathogenic role of a virus.
Not surprisingly, known tumor-associated viruses, such as EBV, 
HBV, HPV16 and HPV18, were among the most frequently detected 
targets. Notably, viral detection based on WGS showed similar 
performance with respect to precision and recall as a targeted PCR 
for HBV, indicating that this approach is sensitive to detect viruses. 
This is particularly true for the common integration verified for 
HBV, HPV16 and HPV18 in our study. In addition, the common 
theme of potential pathomechanistic effects by the genomic inte-
gration of viruses, which were also supported by the observations 
of multiple nearby integration sites in a given tumor genome that 
we report in the present study, has gained further momentum. 
By analyzing the effect of viral integrations on gene expression, we 
identified several links to genes nearby the integration site. In this 
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regard, the frequently observed integration of HBV at the TERT pro-
moter accompanied with the transcriptional upregulation of TERT 
constitutes an intriguing mechanistic example, as the increased 
activity of TERT is a well-understood driver of carcinogenesis49. 
Furthermore, we also linked viral integrations to increased muta-
tions (SNVs and SCNAs) nearby the integration site.
The known causal role of HPV16 and HPV18 in several tumor 
entities, which triggered one of the largest measures in cancer preven-
tion, has been the motivation for extensive elucidation of the patho-
genetic processes involved. Nevertheless, comprehensive analyses of 
WGS and RNA-seq datasets revealed additional novel findings. While 
we confirmed the exclusivity of HPV infection and TP53, CDKN2A 
and TERT mutations in head-and-neck tumors, we could also link 
virus presence to an increase in mutations attributed to the mutational 
signature 2 (ref. 50). These are explained by the activity of APOBEC, 
which—among other effects—changes viral genome sequences as 
a mechanism of cellular defense against viruses51,52. This activation 
could have an important function in introducing further host genome 
alterations and, thus, constitute an important mechanism that drives 
tumorigenesis32,52. In liver cancer, mutations in CTNNB1, TP53 and 
ARID1A, major primary oncogenes in this cancer type and HBV 
infections were confirmed to occur significantly mutually exclusive23. 
Furthermore, the virus-positive head-and-neck cancer samples had a 
significantly higher abundance of T-cell and M1 macrophage expres-
sion signals, which is in agreement with recently described subtypes 
of head and neck squamous cell carcinoma that differ—among other 
features—in virus infection and inflammation features.
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Methods
Identifying potential pathogenic reads. To reduce the number of reads to be 
considered for the pathogen search, we identified potential pathogenic reads by 
using P-DiP (https://github.com/mzapatka/p-dip). On the basis of reads aligned 
to hg19 by BWA53 or STAR54 using the standard PCAWG approach, we identified 
read pairs for which at least one read did not map well to the human genome 
(longest stretch of mapped bases from 20 to 30 bases) and read pairs that were 
unmapped or mapped to NC_007605 (human herpesvirus 4, which is contained 
in the 1000 Genomes version of the hg19 human reference genome), and extracted 
these for further processing. To speed up the extraction, we used bamcollate2 from 
Biobambam2 (v.2.08) 55 as an input stream to the Python script.
Identification of ERVs. The expression of ERVs was analyzed using RNA-seq 
data and aligned STAR sequences based on the settings developed within PCAWG 
(hg19 and Gencode 19). In contrast to the standard pipeline, the reference 
transcripts from Gencode 19 were enriched by adding HERV locations extracted 
from RepeatMasker (http://www.repeatmasker.org, rmsk from UCSC, version 
17/08/03) and Featurecounts (subread-1.5.3)56 applied to identify reads mapping 
to the modified reference transcripts. Resulting reads counts were converted into 
TPM according to Wagner et al.57.
The SEPATH pipeline. Our starting point is to take reads that are not mapped to 
the human genome, using the extracted potentially pathogenic reads. Low quality 
bases (q < 30) were trimmed from the read ends and the TruSeq indexed adapter 
and TruSeq universal adapter were removed using Cutadapt (v.1.8.1)58. Reads less 
than 32 bp were discarded. Additional filtering was performed to remove reads 
that contained more than 5% of Ns or those with low complexity (dust method 
with maximum score of 10) by using Prinseq (v.0.20.3)59. Metagenomic Phylogenic 
Analysis (MetaPhlAn)60,61 was then applied to identify and quantify the presence of 
bacterial and viral populations. MetaPhlAn comes with a curated marker database 
of around 1 million unique clade-specific marker genes identified from reference 
genomes (version 2.0 of the database was used). Reads were aligned against the 
unique marker gene database by using Bowtie2 (v.2.2.1)62 with presets set to 
sensitive. Reads were then counted and normalized giving an estimation of the 
relative abundance for each level of the phylogenetic tree.
Detection and analysis of microbial infectious agents by NGS P-DiP. The 
assembly-based pipeline (P-DiP) was further developed based on a version 
implemented by M.A. and A.G.63. In summary, the pipeline runs preprocessing, 
assembly and BLAST searches and stores processing details and final results in a 
postgreSQL database. For the WGS and RNA-seq analyses, we started with the 
potentially pathogenic reads extracted from the BWA-aligned WGS BAM files. As 
a first step, reads were trimmed based on quality using trimmomatic. Thereafter, 
host reads were subtracted by aligning to the human reference genome (WGS: 
hg19 excluding NC_007605 and hs37d5 and adding phiX; RNA sequencing: 
Homo_sapiens.GRCh37.dna.primary_assembly) using Bowtie2 (v.2.2.8)62. Trinity 
(v.2.0.6)64 was used for the read assembly of WGS reads that were not aligned 
by Bowtie with sufficient quality (not aligned with --very-fast (-D 5 -R 1 -N 0 
-L 22 -i S,0,2.50) to Homo_sapiens.GRCh37.ncrna, Homo_sapiens.GRCh37.
cdna.all or PhiX); for the RNA-seq data we applied idba assembler (v.1.1.3)65. 
Assembled contigs were filtered by size (minimal length of 300 bp). Abundance was 
estimated by remapping all of the reads that did not align to the human reference 
to the assembled contigs by using Bowtie2. Putative PCR duplicates identified 
by mapping location were removed from the abundance count. The taxonomic 
classification of the size-filtered contigs was performed using the BLAST+ package 
(v.2.2.30)66 and nucleotide databases nt (ftp://ftp.ncbi.nlm.nih.gov/blast/db/FASTA/
nt.gz, accessed 15 May 2015) and nr (https://ftp.ncbi.nlm.nih.gov/blast/db/FASTA/
nr.gz, accessed 20 April 2015). For the extraction of pathogen hits R-scripts were 
used to filter the BLAST results (https://github.com/mzapatka/p-dip). In summary, 
for each of the contigs, the best BLAST hits for each segment of the contig 
were considered and the reads aligning to these segments identified. Potential 
contaminants were defined based on the taxonomy annotation in NCBI taxonomy. 
Any taxonomy ID below plasmids (36,549), transposons (2,387), midivariant 
sequences (31,896), insertion sequences (2,673), artificial sequences (81,077) and 
synthetic viruses (512,285) was annotated as potential contamination. Segments 
with higher read counts of these sequences compared to pathogen hits were flagged 
as contaminants and not further considered.
CaPSID description of the analysis workflow. The metagenomic analysis 
pipeline of CaPSID11 starts by first processing a BAM file that contains the reads 
sequenced from a tumor (or normal) sample aligned to the human reference 
sequence (GRCh37/hg19). Reads that did not map to the human reference were 
extracted and filtered for low complexity and quality using the SGA67 preprocessing 
module and then aligned in single-end mode using the Bowtie2 aligner62 to 5,652 
NCBI68 viral reference sequences (RefSeq) and a filter sequence reference database 
composed of 5,242 bacterial and 1,138 fungal reference sequences that were 
also downloaded from the NCBI. To improve the sensitivity and specificity with 
which viral sequences were detected, reads that did not map to any reference with 
Bowtie2 were realigned to the same viral RefSeq database, using the more-sensitive 
aligner SHRiMP2 in local alignment mode69. At the completion of this two-step 
alignment process, reads that aligned to viral reference sequences were annotated 
using the information stored in the genome database of CaPSID, which contains 
full NCBI GenBank and taxa information. Using information from each aligned 
read, CaPSID then calculates the following four metrics: (1) the total number of 
reads (or hits) that aligned across any given viral genome, (2) the total number of 
reads that aligned only across gene regions within any given viral genome, (3) the 
total coverage across each viral genome and (4) the maximum coverage across any 
of the genes in a given viral genome.
Filtering of viral candidates with low significance. For the analysis of the tumor 
WGS or RNA-seq samples, CaPSID reports candidate sequences from dozens of 
different viral genomes, some of which are not related to the cancer phenotype. 
Some of these reported viral hits are also due to a series of experimental and 
computational artifacts. To reduce the number of potential false-positive hits, the 
CaPSID pipeline flags viral genomes that could be the result of artifacts present in 
the sequencing data or those with no obvious relation to cancer phenotype and that 
could be filtered in subsequent steps. The following criteria were used to flag and 
filter for potential viral candidates: (1) flag viral candidates with low coverage, (2) 
flag bacteriophage viral genome sequences, (3) report only viral candidates with a 
read composition different from the one expected when generated from the host’s 
reference GRCh37/hg19 sequence, (4) flag viral candidates that are typically not 
known to infect humans and those with low read abundance and/or low overall 
alignment read accuracy.
In the first step, CaPSID flagged viral genomes with low read count and/or 
coverage using three metrics, including total number of uniquely aligned reads <3, 
total genome coverage <10% and maximum gene coverage <50%. Viral genomes 
with low read count can arise as a result of (1) low read/transcript abundance in the 
human sequenced sample, (2) unspecific alignment between sequenced short reads 
(for example, low complexity reads) and viral reference sequences and (3) for RNA-
seq library preparation in which highly expressed transcripts generally dominate 
over low abundance targets. To limit the reporting of viral genomes with very low 
coverage, we chose to flag all genomes for which the maximum gene coverage was 
<50%. As this lower bound on the maximum gene coverage applied to individual 
genes and not to the complete viral genome, it appears to be unlikely that viruses 
with such low coverage are biologically important. The second step in our filtering 
approach was to flag bacteriophage viral genomes that are most likely not related 
to any cancer phenotype. Bacteriophages are detected as a result of the presence 
of bacteria (or bacterial contamination) in human sequenced samples. The third 
step was used to determine whether the genome coverage observed for each viral 
candidate was different from the one expected to arise from reads that originated 
exclusively from the human reference DNA GRCh37/hg19 sequence. To build 
the CaPSID background model, we used the ART NGS read simulator. The entire 
GRCh37/hg19 sequence reference file is first fed to the ART70 simulator (parameters: 
art_illumina [Illumina platform] -l [read length=100 bp] -f [the fold of read 
coverage to be simulated=100] with default values for indels and substitution rates), 
which then generates single-end (or paired-end) reads and base quality values.
Reads simulated by ART were then aligned to the viral reference sequence 
database using the same alignment approach for reads that originated from tumor 
samples (see above). CaPSID then calculated the four metrics for the GRCh37/
hg19 background model using the alignment information from simulated reads 
that aligned to viral reference sequences. The fourth step consisted of flagging viral 
candidates that were typically not known to infect humans using a dictionary of 
around 130 terms that we compiled from a database of all viruses known to infect 
humans. In addition to the above filtering criteria, CaPSID also considered the read 
abundance associated with each viral candidate sequence (abundance is expressed 
in terms of aligned reads in parts-per million of total number of unmapped reads) 
and the average read percentage identity with which reads aligned to a given viral 
candidate reference sequence.
De novo assembly and taxonomic classification of contigs. The purpose of this 
analysis step is to attempt to characterize potential novel viral sequences at the 
species or subspecies level. Unaligned reads that could not be aligned to any of 
the filter/host or viral reference sequences were assembled into contigs using 
the IDBA algorithm65. Assembled contigs were then masked for repeat regions 
by using RepeatMasker and then filtered for their size and read coverage (contig 
length ≥500 bp and coverage >5×). Resulting contigs were then assigned to 
taxonomic groups at the genus level by using the CSSSCL algorithm48. Contigs 
lacking sequence homology to reference sequences contained in the CaPSID or 
BLAST nucleotide databases with percentage identity <90% were then selected as 
suggestive of the presence of new viral strains/isolates or species.
Defining consensus hits. Identification of the consensus hits was achieved 
by optimizing two features of the individual genus hits: PMER 1 as cut-off 
(Supplementary Note) and percentage identity >90%. The 90% percentage identity 
threshold was determined based on our benchmarking study12 that indicated that 
an alignment-based approach can still accurately characterize viral sequences 
with up to 10% mutation rate (compared with sequences stored in a reference 
database). Lowering the threshold, with which short reads align to any given 
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reference sequence below 90% identity on average, results in a drop of sequence 
coverage due to a high attrition rate of aligned reads, lowering the detection  
rate and thus providing more uncertain characterizations of viral candidates. 
Notably, there was no difference in the PMER distribution of common hits  
across the three pipelines, indicating that a common detection cut-off is 
reasonable (Extended Data Fig. 3b).
The consensus set was restricted to genera that were covered in at least two 
detection pipelines (Extended Data Fig. 1b). Notably, we could not detect any 
more hits with high PMER using the unique search space of P-DiP, indicating 
that almost all of the viral hits from individual pipelines were also screened by 
another pipeline.
Virus integration detection analysis. A subset of viral candidates identified 
to be present in tumor samples by the CaPSID analysis pipeline (parameters 
used: PMER ≥ 1.1 and genome coverage > simulated background model) was 
selected for the detection of viral integration events using the VERSE71 algorithm. 
This subset of viruses included: herpesviruses (HHV1, HHV2, HHV4, HHV5, 
HHV6A/B), simian virus 40 (SV40) and 12 (SV12), human immunodeficiency 
virus (HIV1), human and simian T-cell lymphotropic virus type 1 (HTLV1 and 
STLV1), BK polyomavirus (BKP), human parvovirus B19, mouse mammary tumor 
virus, murine type C retrovirus, Mason–Pfizer monkey virus, HBV, HPV (HPV16, 
HPV18 and HPV6a) and AAV2. Below we describe the steps used for the viral 
integration detection analysis.
Viral integration events in the host can be detected by using paired-end NGS 
technologies that facilitate the detection of genomic rearrangements, as well 
as gene fusions and novel transcripts. VERSE is capable of determining virus 
integration sites within a single base resolution by requiring the presence of both 
chimeric and soft clipped reads. In addition, VERSE improves the detection 
through customizing reference genomes and was shown to substantially enhance 
the sensitivity of the detection of virus integration sites71. VERSE categorizes its 
predictions into one of two classes: (1) a high confidence hit with a single base 
resolution—if there was a sufficient number of soft-clipped reads to support an 
integration locus so that CREST was able to detect it; or (2) a low confidence hit 
with a 10-bp resolution for which CREST failed to detect an integration event 
because of the lack of high-quality soft-clipped reads.
To further limit the false-positive rate associated with viral integration sites, 
we compared results obtained with VERSE to those from a previous study72. Out 
of 64 WGS liver cancer samples with HBV integration events that were reported 
previously72, 50 were part of the PCAWG dataset analyzed in this study. Of 
those, 45 out of 50 tested positive for HBV when analyzed by CaPSID (filtering 
criteria used: PMER ≥ 1.0, genome coverage > host background model and read 
percentage identity ≥89%). In addition, 50 of these WGS samples had 23  
matching whole-transcriptome samples and 22 of these were identified to be 
positive for HBV by CaPSID (filtering criteria used: maximum gene coverage 
≥50%, read percentage identity ≥89% and PMER ≥ 1.0). By combining WGS 
and RNA-seq tumor samples, 47 out of 50 samples tested positive for HBV when 
analyzed by CaPSID.
Using VERSE, virus integration sites were detected in 28 out of 47 (60%) of 
these. This result indicates that for a subset of viral integration events, VERSE 
might be a more stringent approach compared to previously used methods72. This 
can be explained by the fact that VERSE requires both the presence of paired-end 
chimeric and soft clipped reads whereas the previously described method72 relied 
only on paired-end reads. To explore these results further, we compared integration 
sites obtained with VERSE and those described previously72 with an overlapping 
window of 10 bp. Our analysis indicates that among 23 integration sites identified 
by VERSE in RNA-seq data and that overlap with the previously published 
results72, 91% were classified with high confidence hits and only 9% with low (N 
total overlap = 23, high = 21 (91%) and low = 2 (9%)). However, a similar result was 
not observed for integration events found using WGS data (N total overlap = 14, 
high = 6 (43%), low = 8 (57%)), for which the proportion of integration events 
classified as high and low was similar.
Thus, our analysis indicates that one important factor for improving the 
agreement between these two datasets is the confidence level assigned by VERSE 
to each candidate integration site—but only in the case when integration sites 
are detected using RNA-seq data. To reduce the potential number of false-
positive hits, we decided to use all integration sites predicted by VERSE when 
these were obtained using WGS data and only high-confidence calls when using 
RNA-seq data.
Contaminations. On the basis of the presence of vector sequences in the contig 
assembled by P-DiP and the background model from CaPSID, we could identify 
which virus hits originated from common laboratory contaminants or were due 
to sequence similarities to the human genome. In addition, we filtered known 
contaminants (see below). For P-DiP, we filtered all hits that did not have more 
target reads than any artificial sequence (excluding artificial viruses) on an 
individual contig region. Hits caused by vector and other artificial sequences were 
identified by analyzing the assembled contigs for combined hits to viral pathogens 
and artificial sequences. Checking viral hits that occurred at least 40 times in such 
a contig, we could clearly separate contaminants from viral pathogens.
The gammaretrovirus hits (NCBI taxonomy ID 153135; species, murine 
leukemia virus) were also marked as artifacts, on the basis of the additional BLAST 
hits of the corresponding contigs to the Mus musculus genome by P-DiP as well 
as the background model of the CaPSID pipeline, which was designed to limit the 
number of spurious hits. Most of the frequent virus hits prone to contamination 
by artificial sequences were lambdalikevirus, alphabaculovirus, microvirus, 
simplexvirus, hepacivirus, CMV, orthopoxvirus and punalikevirus. However, 
restricting to at least 1 PMER for the potential virus hit contaminants reduced 
these to one CMV case.
Filtering contaminants. We filtered all Microviridae (taxonomy ID 10841) because 
of the phix174 spike-in used during sequencing. Caudovirales (taxonomy ID 
28883), tailed bacteriophages, were removed as they typically infect bacterial hosts. 
Baculoviridae were filtered because these infect insect cells and are commonly 
used in the laboratory. The virus coverage was analyzed by aligning the potentially 
pathogenic reads with BWA-mem to the human hg19 reference genome after 
adding the respective virus reference sequence that was most frequently detected 
within the genus. Coverage was thereafter calculated base specific using BEDTools 
coverage. As we identified EBV in all 14 normal blood controls from ovarian cancer 
that were EBV immortalized, these were removed from the virus hits.
Integration of external PCAWG datasets. We tested for mutual exclusivity, 
for example, between virus detections and driver gene mutations by applying 
DISCOVER22. On the basis of the gene expression data, immune-cell proportions 
were analyzed by CIBERSORT14. For survival analysis, Cox proportional hazards 
analysis was performed using R libraries ‘survival’ and ‘survminer’ for the figures. 
The optimal cut points were identified by maxstat using a previously described 
method73 (library maxstat).
Virus load. The viral load in relation to the human genome equivalents was 
calculated based on the human bases sequenced (read length × number of 
reads mapped to the human genomes), tumor sample purity (if available or 
100% otherwise) assuming a ploidy of two and using a human genome size of 
2,897,310,462 bases (the mappable part of the human genome). This number of 
human genome equivalents was then related to the viral genome equivalents that 
were calculated based on the number of identified viral reads, read length and 
virus genome size.
tumor genome equivalents ¼
read length ´ number of readsmapped to the human genome
mappable human genome size ´ tumor ploidy
´ tumor purity
virus genome equivalents ¼ read length ´ number of viral sequences
virus genome size
virus load ¼ virus genome equivalents
tumor genome equivalents
Human research participants. The ethics oversight for the PCAWG protocol 
was undertaken by the TCGA Program Office and the Ethics and Governance 
Committee of the ICGC. Each individual ICGC and TCGA project that 
contributed data to PCAWG had its own local arrangements for ethics oversight 
and regulatory alignment.
Statistics. If not specified otherwise, we used two-sided Wilcoxon rank-sum 
tests for groups with n > 3. Further details can be found in the Nature Research 
Reporting Summary.
Reporting Summary. Further information on research design is available in the 
Nature Research Reporting Summary linked to this article.
Data availability
Somatic and germline variant calls, mutational signatures, subclonal 
reconstructions, transcript abundance, splice calls and other core data generated 
by the ICGC/TCGA PCAWG Consortium are described in an associated paper10 
and are available for download at https://dcc.icgc.org/releases/PCAWG. Additional 
information on accessing the data, including raw read files, can be found at https://
docs.icgc.org/pcawg/data/. In accordance with the data-access policies of the ICGC 
and TCGA projects, most molecular, clinical and specimen data are in an open tier 
that does not require access approval. To access potentially identifying information, 
such as germline alleles and underlying sequencing data, researchers will need to 
apply to the TCGA Data Access Committee (DAC) via dbGaP (https://dbgap.ncbi.
nlm.nih.gov/aa/wga.cgi?page=login) for access to the TCGA portion of the dataset, 
and to the ICGC Data Access Compliance Office (DACO; http://icgc.org/daco) 
for the ICGC portion. In addition, to access somatic SNVs derived from TCGA 
donors, researchers will need to obtain dbGaP authorization. Datasets described 
specifically in this manuscript can be found in the Supplementary Tables.
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Code availability
The core computational pipelines used by the PCAWG Consortium for 
alignment, quality control and variant calling are available to the public at https://
dockstore.org/search?search=pcawg under the GNU General Public License 
v.3.0, which enables the reuse and distribution of the pipelines. The pathogen-
discovery pipeline P-DiP is available on GitHub (https://github.com/mzapatka/p-
dip). CaPSID is available from GitHub (pipeline, https://github.com/capsid/
capsid-pipeline; webapp, https://github.com/capsid/capsid-webapp).  
The taxonomic classifier CSSSCL is available from GitHub (https://github.com/
oicr-ibc/cssscl).
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Extended Data Fig. 1 | Statistics of analyzed reads from WGS and RNA-seq samples. a, Number of identified candidate pathogen reads used for WGS 
analysis in non-tumor samples and for RNA-seq analysis. Red line represents the median. b, Fraction of analysed reads mapped to phiX174 (green) and 
the human reference genome hg19 (red) and the rest labeled as potentially pathogenic reads (blue). c, Fraction of analysed reads per genome coverage 
separated for virus positive and negative tumor samples across organ systems. Thick black line represents the median. d, Search space overlap for genera 
across the three pipelines. e, Hit space overlap for genera across the three pipelines.
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Extended Data Fig. 2 | Genome coverage of mastadenovirus contamination detected in batches. a, Coverage of the virus genomes summarizing all 
mapped reads across all virus-positive tumor/normal samples. Alignment was done using BWA-mem. b, Mastadenovirus-positive samples ordered based 
on their sequencing date as years, indicating samples from early-onset prostate cancer (EOPC-DE) project across sequencing batches.
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Extended Data Fig. 3 | The distribution of PMER values for consensus hits across pathogen detection pipelines. a, Overlap calculated between three 
pipelines for the cases of shuffled viral hits randomized for their donor. b, PMER distribution of common viral hits detected by all three pipelines. c, Virus 
genome equivalents in relation to human tumor genome equivalents calculated for each sample positive for the virus. d, Co-infection of viruses detected in 
individual tumor samples. The fraction of overlap between two viruses were calculated as the number of shared samples divided by the smaller set.
NATuRE GENETICS | www.nature.com/naturegenetics
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Extended Data Fig. 4 | See next page for caption.
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Extended Data Fig. 4 | Specific findings for lymphocrypto- and roseolovirus, HBV and EBV. Overall contribution of immune cells across organ system in 
samples positive or negative for lymphocryptovirus and roseolovirus. Tukey boxplot indicates the median by the middle line and the 25–75th percentiles 
by the box. The whiskers were drawn up to the 1.5 interquartile range from the lower and upper quartile. b, Comparison of histopathologically detected 
HBV in liver cancer with the PMERs detected in WGS. Precision and recall of the PCR based HBV test versus the consensus calls from WGS data. Red 
dot indicates the PMER cut-off of 1. c, Relation of PMER for EBV detections in tumor and normal samples across organ system and normal tissue type. d, 
Epstein-Barr virus expression presenting lytic (red) and latent (green) genes across organ systems. Reads were counted after alignment with kallisto to the 
EBV reference transcriptome (see Methods).
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Extended Data Fig. 5 | Expression of stem cell markers in relation to HERV expression. Expression values of KLF4, POU5F1 and SOX2 in relation to 
transcriptional activity of HERVs (ERV, ERV1, ERVK, ERVL, ERVL.MaLR) for 908 tumor samples. Correlation coefficient (R) presented is calculated using 
Spearman Rank Correlation.
NATuRE GENETICS | www.nature.com/naturegenetics
Articles NATuRE GENETICs
Extended Data Fig. 6 | Overall Survival analysis of endogenous retrovirus expression in different tissue types. Cut-offs were defined by maxstat R 
package using log-rank test and. P values were corrected for multiple testing of variable cut-offs using Lau2 method. Analyzed were all tissue types with 
more than 40 cases and at least 15 events. Number of patients at risk is provided separated by high or low expression groupings based on the tpm cutoff 
for the respective ERV family provided in the title of individual panels. P-value of the log-rank test is provided for each analysis.
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Extended Data Fig. 7 | Number of viral integration events as a function of the chromosome and genomic location. a, Shows the number of viral 
integration events detected for HBV, HPV16 and HPV18 as a function of the human chromosome. Numbers within each stacked bar plot represent the 
number of integration events detected for each virus and within each chromosome. b, Shows the percentage of the total number of integration events 
detected for each chromosome averaged over three viral types shown in panel A. c, Number of viral integration events detected for HBV, HPV16 and 
HPV18 as a function of the host’s genomic location. Numbers within each stacked bar plot represent the number of integration events detected for each 
virus and within each genomic location. d, Shows the percentage of the total number of integration events detected within each genomic location averaged 
over three viral types shown in panel C. e, Shows the number of HBV integration events detected in liver cancers in the host’s gene coding and/or gene 
promoter regions. Stacked bar plot represents the number of integration events detected within each sample and each gene, each sample is indicated 
using the color code shown in the legend to the right. f, Shows the number of HPV18 integration events detected in head/neck and cervical cancers in the 
host’s gene coding or gene promoter regions. g, Shows the number of HPV16 integration events detected in head/neck and cervical cancers in the host’s 
gene coding and/or gene promoter regions.
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Extended Data Fig. 8 | See next page for caption.
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Extended Data Fig. 8 | Comparison of the somatic copy number alterations (SCNA) and single nucleotide variants (SNVs) for samples with and without 
HPV and HBV integrations into human genome. a, Boxplots showing the number of SCNA detected in head/neck and cervical cancers: HPV16+(red) 
vs HPV16- (grey) samples. SCNAs are calculated using three different distances from the integration site: i) greater than 1 Megabases (Mbp), ii) exactly 
+/− 1 Mbp away, and iii) below 1 Mbp (n = 17 virus integrations). b, Boxplots showing the number of SCNAs detected in head/neck and cervical cancers 
with and without HPV18 integrations (n = 8 virus integrations). c, Number of SNVs detected in head/neck and cervical cancers with and without HPV16 
integrations. Number of SNVs are calculated using three different ranges for the human genome: i) SNVs within the nearest gene to the virus integration 
site (maximum: 50Kb), ii) SNVs at the location of the viral integration site in the chromosomal region +/− the position of the second breakpoint located 
in the viral sequence, and iii) SNVs around 10 kb of the viral integration site. Blue triangles indicate the mean values. (n = 87 virus integrations) d, Number 
of SNVs detected in liver cancers with and without HBV integrations (n = 109 virus integrations). e. Number of SNVs detected in head/neck and cervical 
cancers with and without HPV18 integrations (n = 14 virus integrations). In all Tukey boxplots, black line in the middle represents median and the 25–75th 
percentiles by the box. The whiskers were drawn up to the 1.5 interquartile range from the lower and upper quartile. f, Expression of tumors and normal 
samples for long noncoding RNAs with and without HPV16 integrations near to the integration site.
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Extended Data Fig. 9 | Contigs from de novo assembly identified as possibly originating from novel viral species or strains. Barplot showing the number 
of contigs obtained using the CaPSID’s de novo assembly step (see Methods) within each genus. Taxonomic classification for each contig was performed 
using the CSSSCL algorithm. Each of the 29 contigs considered for this plot had to have a sequence homology <90% when aligned to any known  
sequence contained by the latest nucleotide BLAST database. The legend to the right indicates the following ICGC project codes: BLCA—bladder cancer, 
CESC—cervical cancer, CLLE—chronic lymphocytic leukemia, HNSC—head and neck, LIHC and LIRI—liver cancer, PBCA—pediatric brain cancer, and 
STAD—stomach cancer.
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Statistics
For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one- or two-sided 
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested
A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) 
AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
Give P values as exact values whenever suitable.
For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated
Our web collection on statistics for biologists contains articles on many of the points above.
Software and code
Policy information about availability of computer code
Data collection Data and metadata were collected from International Cancer Genome Consortium (ICGC) consortium members using custom software 
packages designed by the ICGC Data Coordinating Centre. The general-purpose core libraries and utilities underlying this software have 
been released under the GPLv3 open source license as the "Overture" package and are available at https://www.overture.bio. Other data 
collection software used in this effort, such as ICGC-specific portal user interfaces, are available upon request to contact@overture.bio.
Data analysis The workflows executing core WGS alignment, QC and variant-calling software are packaged as executable Dockstore images and 
available at: https://dockstore.org/search?labels.value.keyword=pcawg&searchMode=files. Individual software components are as 
follows: BWA-MEM v0.78.8-r455; DELLY v0.6.6; ACEseq v1.0.189; DKFZ somatic SNV workflow v1.0.132-1; Platypus v0.7.4; ascatNgs 
v1.5.2; BRASS v4.012; grass v1.1.6; CaVEMan v1.50; Pindel v1.5.7; ABSOLUTE/JaBbA v1.5; SvABA 2015-05-20; dRanger 2016-03-13; 
BreakPointer 2015-12-22; MuTect v1.1.4; MuSE v1.0rc; SMuFIN 2014-10-26; OxoG 2016-4-28; VAGrENT v2.1.2; ANNOVAR v2014Nov12; 
VariantBAM v2017Dec12; SNV-Merge v2017May26; SV-MERGE v2017Dec12; DKFZ v2016Dec15. The identification of potential 
pathogenic reads was speed up by Biobambam2 v2.0.8. For HERV identifcation we used repeatmasker rmsk version 17/08/03 and 
Featurecounts from subread-1.5.3. SEPATH Cutadapt v1.8.1,Prinseq v0.20.3, MetaPhlAn v2.0, BowTie2 v2.2.1.  
The pathogen discovery pipeline P-DIP is available on github at https://github.com/mzapatka/p-dip.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. 
We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
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Policy information about availability of data
All manuscripts must include a data availability statement. This statement should provide the following information, where applicable: 
- Accession codes, unique identifiers, or web links for publicly available datasets 
- A list of figures that have associated raw data 
- A description of any restrictions on data availability
WGS somatic and germline variant calls, mutational signatures, subclonal reconstructions, transcript abundance, splice calls and other core data generated by the 
ICGC/TCGA Pan-cancer Analysis of Whole Genomes Consortium are available for download at https://dcc.icgc.org/releases/PCAWG. Additional information on 
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accessing the data, including raw read files, can be found at https://docs.icgc.org/pcawg/data/. In accordance with the data access policies of the ICGC and TCGA 
projects, most molecular, clinical and specimen data are in an open tier which does not require access approval. To access potentially identification information, 
such as germline alleles and underlying sequencing data, researchers will need to apply to the TCGA Data Access Committee (DAC) via dbGaP (https:// 
dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=login) for access to the TCGA portion of the dataset, and to the ICGC Data Access Compliance Office (DACO; http:// 
icgc.org/daco) for the ICGC portion. In addition, to access somatic single nucleotide variants derived from TCGA donors, researchers will also need to obtain dbGaP 
authorization. 
Data sets described specifically in this manuscript can be found in the supplementary tables.
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Life sciences study design
All studies must disclose on these points even when the disclosure is negative.
Sample size We compiled an inventory of matched tumour/normal whole cancer genomes in the ICGC Data Coordinating Centre. Most samples came 
from treatment-naïve, primary cancers, but there were a small number of donors with multiple samples of primary, metastatic and/or 
recurrent tumours. Our inclusion criteria were: (i) matched tumour and normal specimen pair; (ii) a minimal set of clinical fields; and (iii) 
characterisation of tumour and normal whole genomes using Illumina HiSeq paired-end sequencing reads. 
We collected genome data from 2,834 donors, representing all ICGC and TCGA donors that met these criteria at the time of the final data 
freeze in autumn 2014. We chose the largest possible sample size given alls ICGC and TCGA samples meeting the defined criteria.
Data exclusions After quality assurance, data from 176 donors were excluded as unusable. Reasons for data exclusions identified after initial quality check 
included inadequate coverage, extreme bias in coverage across the genome, evidence for contamination in samples and excessive sequencing 
errors (for example, through 8-oxoguanine).
Replication In order to evaluate the performance of each of the mutation-calling pipelines and determine an integration strategy, we performed a 
largescale deep sequencing validation experiment. We selected a pilot set of 63 representative tumour/normal pairs, on which we ran the 
three core pipelines, together with a set of 10 additional somatic variant-calling pipelines contributed by members of the SNV Calling Working 
Group. Overall, the sensitivity and precision of the consensus somatic variant calls were 95% (CI90%: 88-98%) and 95% (CI90%: 71-99%) 
respectively for SNVs. For somatic indels, sensitivity and precision were 60% (34-72%) and 91% (73-96%) respectively. Regarding SVs, we 
estimate the sensitivity of the merging algorithm to be 90% for true calls generated by any one caller; precision was estimated as 97.5% - that 
is, 97.5% of SVs in the merged SV call-set have an associated copy number change or balanced partner rearrangement. 
For the virus detection pipeline we identified the cutoffs for virus detections based on a validation set and evaluated the performance 
comparing to the histopathological gold standard HBV PCR in 228 tumors identifying a specificity of 96.1% and a sensitivity of 84.0%. 
Randomization No randomisation was performed as we included all possible samples meeting the criteria explained above.
Blinding No blinding was undertaken as it is irrelevant for the study because we searched for viruses linked to tumors in an exploratory way.
Reporting for specific materials, systems and methods
We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, 
system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response. 
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Population characteristics Patient-by-patient clinical data are provided in the marker paper for the PCAWG consortium (Extended Data Table 1 of that 
manuscript). Demographically, the cohort included 1,469 males (55%) and 1,189 females (45%), with a mean age of 56 years 
(range, 1-90 years). Using population ancestry-differentiated single nucleotide polymorphisms (SNPs), the ancestry distribution 
was heavily weighted towards donors of European descent (77% of total) followed by East Asians (16%), as expected for large 
contributions from European, North American and Australian projects. We consolidated histopathology descriptions of the 
tumour samples, using the ICD-0-3 tumour site controlled vocabulary. Overall, the PCAWG data set comprises 38 distinct tumour 
types. While the most common tumour types are included in the dataset, their distribution does not match the relative 
population incidences, largely due to differences among contributing ICGC/TCGA groups in numbers sequenced.
Recruitment Patients were recruited by the participating centres following local protocols. As different numbers of patients from the 
individual cancer entities are included in the data set this distribution introduces a bias that we controlled by perfoming also 
cancer entity specific analyses.
Ethics oversight The Ethics oversight for the PCAWG protocol was undertaken by the TCGA Program Office and the Ethics and Governance 
Committee of the ICGC. Each individual ICGC and TCGA project that contributed data to PCAWG had their own local 
arrangements for ethics oversight and regulatory alignment.
Note that full information on the approval of the study protocol must also be provided in the manuscript.
